How our research benefits to society
In this multicentre randomized trial we will investigate whether oral esketamine is non-inferior to ECT after eight weeks of individually optimized treatment and compare the long-term effectiveness. We will also investigate whether oral esketamine is more patient friendly than ECT with respect to treatment burden, side effects, and tolerability. And if treatment with oral esketamine is more cost-effective compared to ECT. The answers to these questions will be used by Zorginstituut Nederland to decide whether oral esketamine in the future can be reimbursed for severe depression. Parnassia/PsyQ Den Haag, LUMC Leiden, Pro Persona Nijmegen and GGZinGeest/Amsterdam UMC in Amsterdam will all be participating in this UCP/UMCG based study.